Advertisement

Topics

NICE wants to axe funding for two thyroid cancer drugs

07:44 EDT 23 Aug 2017 | pharmaphorum

NICE says two thyroid cancer drugs should not be used on the NHS because of their cost and uncertain survival benefits. Ipsen’s Cometriq (cabozantinib) and Sanofi’s Caprelsa (vandetanib) are both covered by the Cancer Drugs Fund (CDF), a...

Original Article: NICE wants to axe funding for two thyroid cancer drugs

NEXT ARTICLE

More From BioPortfolio on "NICE wants to axe funding for two thyroid cancer drugs"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Thyroid Disorders
The thyroid is a butterfly-shaped gland in the neck, just above thecollarbone and is an endocrine gland that make hormones. These Thyroid hormones control the rate of many activities in the body, including how fast the body burns calories and how fast th...